Postoperative radiotherapy in Stage I endometrial adenocarcinoma

Objective: To evaluate postoperative whole pelvic radiation for high-risk patients with Stage I endometrial adenocarcinoma.

Methods: One hunderd and twenty-two patients with irregular premenopausal or postmenopausal haemorrhage were included into the study. Fractional curettage was performed in all cases. When the pathohistological report confirmed endometrial adenocarcinoma, abdominal hysterectomy with bilateral salpingo-oophorectomy was performed. Low-risk patients include women with Stage IA tumours and Stage IB grade 1 or 2 histology. High-risk group include patients with Stage IB grade 3 tumours and Stage IC carcinomas. High-risk patients received whole pelvic radiotherapy between two and four weeks after surgery.

Results: Eighty-two patients (67.21%) were low-risk and forty patients (32.79%) were high-risk. In the low-risk group of patients, CA-125 was negative in ten cases and positive in 72 patients with a mean value of 30.12 +/- 12.42 U/ml serum. In the high-risk group of the patients, CA-125 was negative in two cases and positive in 38 patients with a mean value of 60, 48 +/- 20, 14 U/ml serum. Locoregional recurrences were diagnosed in four patients (4.87%) in the surgery group and in two patients (5.00%) assigned to radiotherapy. The incidence of distant metastases was 2.43% in the surgery group and 2.50% in the radiotherapy group. Overall survival at five years was 90.25% in the low-risk group and 87.50% in the high-risk group of patients.

Conclusion: Five-year overall survival, locoregional and distant metastasis were similar in the low-risk and high-risk groups of patients. That emphasizes the value of whole pelvic radiation in patients with unfavourable prognostic factors in Stage I endometrial cancer.

Stage I endometrial adenocarcinoma; High-risk patients; Postoperative pelvic radiotherapy

[1] Aalders J., Abeler V., Kolstad P., Onsrud M.: "Postoperative external irradiation and prognostic parameters in stage I endometrial clinical and histopathologic study of 540 patients". Obstet. Gynecol., 1980, 56, 419.

[2] Naumann R.W.: "The role of radiation therapy in early endometrial cancer". Curr. Opin. Obstet. Gynecol., 2002, 14, 75.

[3] Larson D.M., Broste S.K., Krawisz B.R.: "Surgery without radiotherapy for primary treatment of endometrial cancer". Obstet. Gynecol., 1998, 91, 355.

[4] Benedet J.L., Pecorelli S.: "Staging classifications and clinical practice guidelines of gynecologic cancers". J. Gynecol. Obstet., 2000, 70, 207.

[5] Kurihara T., Mizunuma H., Ohara M., Andoh Kazneno., Ibuki Y., Nishimura T.: "Determination of a normal level of serum CA l 25 in postmenopausal women as a tool for preoperative evaluation and postoperative survellance of endometrioal carcinoma". Gynecol. Oneal., 1998, 69, 192.

[6] Dotters D.J.: "Preoperative CAl25 in endometrial cancer: is it useful?". Am. J. Obstet. Gynecol., 2000, 182, 1328.

[7] Koper N.P., Massuger L.F., Thomas C.M., Kiemeney L.A., Verbeek A.L.: "Serum CA!25 measurements to identify patients with endometrial cancer who require lymphadenectomy". Anticancer Res., 1998, 18, 1897.

[8] Kukura V., Zaninovic I., Hrdina B.: "Concentrations of CA-125 tumor marker in endometrial carcinoma". Gynecol. Oncol., 1990, 37, 388.

[9] Kukura V., Zovko G., Ciglar S., Markulin-Grgic L., Santek F., Podgajski M., Duic Z： “Serum CA-125 tumor marker in endometrial adenocarcinoma". Eur. J. Gynaecol. Oncol., 2003, 24 (2), 151.

[10] Alcazar J.L., Jurado M., Lopez-Garcia G.: "Comparative study of transvaginal ultrasonography and CA 125 in the preoperative evaluation of myometrial invasion in endometrial carcinoma". Ultrasound Obstet. Gynecol., 1999, 14, 210.

[11] Trimble E.L., Kosary C., Park R.C.: "Lymph node sampling and survival in endometrial cancer". Gynecol. Oncol., 1998, 71, 340.

[12] Mohan D.S., Samuels M.A., Selim M.A.: "Long-term outcomes of therapeutic pelvic lymphadenectomy for Stage I endometrial adenocarcinoma". Gynecol. Oneal., 1998, 70, 165.

[13] Grigsby P.W.: "The role of iirradiiatii on in endometrial cancer". Oncol. Spectr., 2001, 2, 343.

[14] Poulsen H.K., Jacobsen M., Bertelsen K.: "Adjuvant radiation therapy is not necessary in the management of endometrial carcinoma Stage I, low-risk cases". Int. J. Gynecol. Cancer, 1996, 6, 38.

[15] Podczaski E., Kaminski P., Gurski K.: "Detection and patterns of treatment failure in 300 consecutive cases of "early" endometrial cancer after primary surgery". Gynecol. Oncol., 1992, 47, 323.

[16] Irwin C., Levin W., Fyles A., Pintili M., Manchu) L., Kirkbride P.: "The role of adjuvant radiotherapy in carcinoma of the endometrium - results in 550 patients with pathological stage I disease". Gynecol. Oneal., 1998, 70, 247.

[17] Creutzberg C.L., van Puten W.L., Koper P.C., Lybeert M.L., Jobsen J.J., Warlam-Rodenhuis C.C. et al.: "Surgery and postoperative radiotherapy versus surgery alone for patients with stage I endometrial carcinoma: multicentre randomised trial". Lancet, 2000, 355, 1404.

[18] Anderson J.M., Stea B., Hallum A.V., Rogoff E., Childers J.: "High-dose-rate postoperative alone for stage 1B and IC endometrial cancer". J. Radiat. Oneal. Biol. Phys., 2000, 46, 417.

[19] Alektiar K.M., McKee A., Venkatraman E., McKee B., Zelefsky M.J., Mychalczak B.R. et al.: "Intravaginal high-dose-rate brachytherapy for Stage 1B (FIGO Grade 1, 2) endometrial cancer". J. Radiat. Oneal. Biol. Phys., 2002, 53, 707.

[20] Yalman D., Ozsaran Z., Anacak Y., Celik 0.K., Ozkok S., Ozsaran A. et al.: "Postoperative radiotherapy in endometrial carcinoma:analysis of prognostic factors in 440 cases". Eur. J. Gynaecol. Oncol., 2000, 21, 311.

[21] Ayhan A., Taskiran C., Celik C., Guney I., Yuce K., Ozyar E. et al.: "Is there a survival benefit to adjuvant radiotherapy in high-risk surgical stage I endometrial cancer?". Gynecol. Oncol., 2002, 86, 259.